Real World GLP-1 Results vs Clinical Trials: What the Headline Numbers Can and Cannot Promise

Dr. Anjmun Sharma, MD explains why everyday GLP-1 outcomes differ from trial averages, and how to give yourself the conditions the trials actually tested.

Real world GLP-1 results vs clinical trials: the honest answer is that trial results come from selected participants who received close support, structured dosing, and stayed on therapy. Everyday results vary because adherence, follow-up, dose access, and starting health differ from person to person. That is why the average outcome outside a trial often lands below the headline figure, and why results vary by individual.

I spend a surprising amount of my clinic time un-teaching numbers. A patient arrives having read that a medication produced roughly 15 percent average weight loss, or nearly 21 percent, and they carry that number around like a promise. It was never a promise. It was the average result of a specific group of people, treated in a specific way, for a specific length of time. Understanding what sat behind that average is the most useful piece of expectation-setting I can offer, so let me walk through it the way I would across the desk.

Why do trial results look better than everyday results?

Start with who gets into a trial. Large studies screen applicants against strict criteria and enroll people who are likely to complete the protocol. In the STEP-1 trial, participants taking semaglutide lost about 14.9 percent of body weight on average over the study period. In SURMOUNT-1, tirzepatide at the highest studied dose produced an average of about 20.9 percent. Those numbers are real. They are also the product of unusually favorable conditions. (Semaglutide is sold under the brand names Ozempic and Wegovy, trademarks of Novo Nordisk; tirzepatide under Mounjaro and Zepbound, trademarks of Eli Lilly. My clinic is not affiliated with either company.)

Consider what a trial participant received beyond the medication itself. The drug was supplied at no cost for the full study, so nobody stopped because a price changed or a pharmacy ran out. Doses were increased on a defined schedule, with staff checking in about side effects and adjusting the plan. Participants had regular visits, lifestyle counseling, and a team whose job was to keep them in the study. Attendance was tracked. Missed appointments were followed up. Very few people in ordinary life receive that intensity of structure, and structure turns out to matter almost as much as pharmacology.

Then there is time on therapy. The headline averages describe people who, for the most part, took the medication as directed for more than a year. A person who stops at month three has not received the treatment the trial measured. Their result is not a smaller version of 14.9 percent; it is the result of a different, shorter exposure. Averaging many such experiences together is exactly why real-world figures drift downward from trial figures. Nothing mysterious is happening. The inputs changed, so the outputs changed.

What makes real-world results vary so much?

In my clinic, when someone's progress falls short of what they expected, I can almost always trace it to circumstances rather than to the person. The same handful of drivers come up again and again, and none of them is a character flaw.

Early discontinuation leads the list. Cost pressures, insurance changes, a rough week of nausea that nobody helped manage, a move, a new job, a pharmacy backorder. Life interrupts treatment in ways a trial protocol is specifically designed to prevent. When therapy stops in the first few months, the full effect simply never has the chance to arrive, because these medications build their benefit gradually as the dose is titrated up.

Titration itself is a second driver. The trial averages came from people who climbed the dose ladder on schedule. Outside a trial, some people stay parked at a starting dose for months, sometimes because of supply gaps, sometimes because nobody was watching the calendar, sometimes because side effects were never addressed and a higher dose felt unwise. A starting dose is not the studied treatment. Judging the medication from it is like judging a course after the first lecture.

Supply and product variation add another layer. During shortages, some patients moved between pharmacies, doses, or formulations, including compounded semaglutide or tirzepatide. Compounded versions are not FDA-approved and are not identical to the brand versions, and results vary by individual. I am not criticizing anyone's choice here; I am pointing out that every switch introduces variability that the trials, with their single consistent product, never had to absorb.

Finally, the quiet drivers: follow-up intensity and lifestyle support. Trial participants got both automatically. In everyday care, a patient may go months without a check-in, with no one adjusting the anti-nausea plan, no one asking about protein intake or resistance exercise, no one treating a plateau as a solvable problem. Starting health differs too. Thyroid status, sleep apnea, medications that promote weight gain, years of prior dieting; all of it shifts an individual's curve. None of this is a failure of the patient, and none of it is unique to any one type of clinic. These are conditions, and conditions can be changed.

How do I give myself trial-like conditions?

Here is the encouraging part. Almost everything that separated trial participants from everyday patients is reproducible. Not the free medication, admittedly. But the structure, yes.

• Keep scheduled follow-up. Regular visits, especially during the first months of titration, are where side effects get managed and doses get adjusted instead of abandoned.
• Complete the titration before you judge the medication. The published averages describe people at studied doses over many months, not people at week six on a starting dose.
• Do the lifestyle work the trials included. Every major study paired the drug with diet and activity counseling. Adequate protein, some resistance training, and reasonable sleep are part of the studied treatment, not extras.
• Treat problems as problems, not exits. Nausea, a plateau, a cost squeeze: each has options worth discussing with your clinician before quietly stopping.
• Plan for duration honestly. Decide up front whether the schedule and budget can support a real course of treatment, because a treatment you can sustain beats a stronger one you abandon.

What can a trial promise you? Direction and plausibility. It tells you the medication works, on average, under good conditions. What it cannot promise is your personal number. Some of my patients outperform the trial averages. Others land below them and still transform their health, their labs, and their daily life. Both outcomes are real medicine working in real circumstances.

The standard I hold my own practice to, and the one I would encourage you to expect anywhere you seek care, is simple: consistent follow-up, honest expectations set from the actual evidence, and treatment of the medication as one tool inside a larger plan. Those are the conditions the trials quietly tested alongside the drug, and any good care setting, in person or by telehealth, can recreate them. When patients ask me whether they will match the headline figure, I tell them the truth: I cannot promise the number, but together we can build the conditions that gave the number its best chance.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.